Clinical evaluation of a pasteurized factor XIII concentrate administration in Henoch-Schönlein purpura. Japanese Pediatric Group.
Arthral, abdominal and renal symptoms in Henoch-Schönlein purpura (HSP) were scored. Coagulation factor XIII (F XIII) activity was determined in fifty-six children with HSP and the correlation with the severity score of the clinical symptoms was investigated. As a result, it was found that the decrease in F XIII level was correlated with the severity score of clinical symptoms, particularly abdominal symptoms. Based on the results, a controlled study was performed in 24 cases with moderate symptoms divided into a group treated with F XIII concentrate and a non-treated group to investigate clear-cut efficacy as a next study. In three days after the administration the symptoms were improved remarkably in accordance with the increase of F XIII level compared with non-treated group and scoring of clinical symptoms was confirmed to be useful for assessing the application of the F XIII concentrate to HSP.
Fukui
H
H
Dept. of Pediatrics, Nara Medical College, Japan.
Kamitsuji
H
H
Nagao
T
T
Yamada
K
K
Akatsuka
J
J
Inagaki
M
M
Shike
S
S
Kobayashi
Y
Y
Yoshioka
K
K
Maki
S
S
D015746:Abdominal Pain / Q000188:drug therapy; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005176:Factor XIII / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011695:IgA Vasculitis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D007596:Joints / Q000503:physiopathology; D007668:Kidney / Q000503:physiopathology; D008297:Male; D015337:Multicenter Studies as Topic
D005176:Factor XIII